drugset / Trial / NCT05132777
Efficacy and Safety of JMT101 Combined With Osimertinib in Patients With Non-Small Cell Lung Cancer
Phase 2
Unknown
155 enrolled
Shanghai JMT-Bio Inc.
CSPC ZhongQi Pharmaceutical Technology Co., Ltd. · collab
NaSingle-groupOpen-labelTreatment
Summary
This study is a phase II, open label, multi-center study to evaluate the efficacy and safety of JMT101 combined with Osimertinib in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring EGFR exon 20 insertion mutations.
Timeline
- Start
- 2021-11-20
- Primary completion
- 2023-09-30
- Completion
- 2024-09-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BECOTATUG | Monoclonal antibody | 6 mg/kg | Intravenous |
| Subject | Osimertinib | Small molecule | 160 mg | Oral |